How to Value a Hospice or Palliative Care Organization in 2026

I've written before about hospice agency valuation and the dynamics driving that market. But the broader end-of-life and serious illness care landscape extends well beyond traditional hospice, and the M&A activity in palliative care, grief services, and community-based programs is accelerating in ways that deserve separate attention.

Palliative care is distinct from hospice — it doesn't require a terminal diagnosis, can be provided alongside curative treatment, and serves a much larger patient population. That distinction is driving both clinical innovation and buyer interest. Let me walk through how valuation works across this broader category.

The Expanding Definition of Palliative Care

Traditional hospice requires a physician to certify a prognosis of six months or less. Palliative care has no such limitation. A patient with COPD, heart failure, cancer, or any serious illness can receive palliative services — symptom management, care coordination, goals of care conversations, psychosocial support — while continuing to pursue curative treatment.

This broader scope means the addressable market for palliative care is roughly 10x larger than hospice. An estimated 6 million Americans have serious illness that would benefit from palliative services, but only about 1.7 million receive hospice care. The gap represents both an unmet clinical need and a market opportunity that buyers are pricing into their acquisition models.

Medicare's Community-Based Palliative Care model — still evolving through CMS Innovation Center demonstrations — is creating a reimbursement pathway for non-hospice palliative services that didn't exist five years ago. Organizations that have been providing palliative care (often at a loss or through grant funding) now have a pathway to sustainable reimbursement, and that changes the valuation calculus entirely.

How Palliative Care Organizations Generate Revenue

Revenue models in palliative care are more varied than hospice, where Medicare per diem is dominant. Palliative care organizations typically draw from multiple streams:

• Fee-for-service billing:Palliative care physician and advanced practice provider visits billed under standard E&M codes (99214, 99215) and advance care planning codes (99497, 99498). Margins are moderate but predictable.
• Value-based contracts: Shared savings arrangements with Medicare Advantage plans and ACOs, where palliative care reduces hospitalizations and ER visits. These contracts pay based on total cost of care savings, which can be substantial.
• Hospital consulting:Many palliative care programs operate within hospital systems as internal consultative services. They're funded by the hospital because they reduce length of stay, improve patient satisfaction (HCAHPS scores), and reduce readmissions.
• Hospice bridge: Organizations that operate both palliative care and hospice programs create a clinical continuum where palliative care patients transition to hospice when appropriate, improving hospice length of stay and reducing late enrollments.
• Grant and philanthropic funding:Community-based palliative programs still rely on grants and donations, particularly in underserved areas. This revenue isn't sustainable or scalable, and buyers generally exclude it from their valuation models.

Quality Metrics That Drive Valuation

In hospice and palliative care, quality metrics directly affect reimbursement and, by extension, valuation. Buyers scrutinize these numbers as carefully as they examine financials.

CAHPS Hospice Survey scores measure patient and family satisfaction across multiple domains — communication, timeliness, respect, emotional support, symptom management. CMS publishes these scores publicly through the Hospice Compare website, and they factor into the Hospice Quality Reporting Program (HQRP). Low scores trigger payment reductions.

Timely initiation of care — the percentage of patients receiving an initial visit within 48 hours of admission — is a quality measure that signals operational capacity. Organizations that consistently achieve 95%+ timely initiation demonstrate that they have the clinical staff and geographic coverage to serve their census without gaps.

Hospice Outcomes and Patient Evaluation (HOPE), which replaced the Hospice Item Set in 2025, is the new standardized assessment tool. Early adoption and clean data submission signals operational sophistication that buyers value.

Star ratingsare increasingly important. CMS's hospice star rating system (5 stars maximum) gives patients and referral sources a quick quality indicator. A 4- or 5-star rating is a marketing advantage and a valuation driver. A 1- or 2-star rating is a red flag that can reduce your multiple by 1-2 turns.

The Pediatric Hospice and Palliative Care Premium

Pediatric hospice and palliative care is a niche that most providers avoid because of its clinical complexity and emotional demands. That avoidance creates scarcity, and scarcity creates premium valuations for the organizations that do it well.

Pediatric programs require specialized clinical staff — nurses, social workers, and child life specialists experienced in age-appropriate symptom management and family support. Perinatal hospice (supporting families through terminal fetal diagnoses) is even more specialized. The training and recruitment costs are higher, but the organizations that build these capabilities have something that can't be easily replicated.

From a payer perspective, pediatric hospice benefits from the concurrent care provision in the ACA — children can receive hospice services while continuing curative treatment. This eliminates the "either/or" barrier that keeps many adult patients from electing hospice, resulting in longer lengths of stay and more complete revenue capture.

Buyers building comprehensive end-of-life platforms actively seek pediatric capabilities because they fill a gap in the continuum that differentiates their platform in referral relationships with children's hospitals and pediatric oncology programs.

Grief Counseling and Bereavement Services

Hospice regulations require providers to offer bereavement services to families for 13 months after a patient's death. Most hospices treat this as a cost center — a compliance requirement they meet minimally. But a growing number of organizations are building robust grief counseling programs that extend beyond the regulatory minimum and serve the broader community.

Community grief programs — open to anyone, not just hospice families — generate referral relationships, brand awareness, and community goodwill. More practically, they create a pipeline of families who become aware of the organization's hospice and palliative services before they need them. This upstream relationship building reduces customer acquisition costs and improves admission conversion rates.

While grief services alone don't generate significant revenue, their strategic value in building the referral pipeline is something sophisticated buyers understand and factor into their models.

Advance Care Planning as a Revenue Stream

Medicare reimburses for advance care planning (ACP) conversations — helping patients document their preferences for end-of-life care through advance directives, POLST forms, and goals of care discussions. CPT codes 99497 and 99498 pay approximately $86 and $75 respectively for the initial and additional 30-minute increments.

Organizations that systematically provide ACP services — either through dedicated facilitators or as part of palliative care visits — create a revenue stream while performing a service that improves care quality downstream. Patients with documented advance directives are more likely to receive goal-concordant care, less likely to have unwanted hospitalizations, and more likely to elect hospice when appropriate.

For organizations being valued, a structured ACP program demonstrates clinical sophistication and creates a measurable link between upstream services and downstream patient capture. Buyers see it as evidence of an integrated care model rather than a transactional hospice operation.

Regulatory Risk and Compliance in Valuation

Healthcare M&A always involves regulatory risk, and hospice and palliative care is no exception. OIG scrutiny of hospice has intensified, with investigations focusing on length of stay patterns, live discharge rates, and diagnosis-specific utilization. The "hospice fraud" headlines have made buyers more cautious about compliance.

Buyers evaluate compliance risk through several lenses:

• Average length of stay (ALOS):An ALOS significantly above the national median (~92 days for Medicare hospice) triggers scrutiny. Extremely long stays may indicate patients who aren't truly terminal, which is a compliance red flag.
• Live discharge rates: High live discharge rates may indicate patients being enrolled too early. Low rates may indicate patients being kept on service beyond clinical appropriateness.
• Diagnosis mix: An unusually high concentration of dementia and debility diagnoses (historically targeted by OIG) versus cancer and organ failure is a pattern buyers investigate.
• Survey history: State survey deficiencies, conditions of participation issues, and any history of Medicare sanctions are deal factors that affect both price and structure.

Organizations with clean compliance records, documented clinical eligibility processes, and active compliance programs command premium multiples. Those with compliance concerns face either lower multiples or aggressive indemnification requirements that shift risk back to the seller.

Who's Buying Palliative Care Organizations

The buyer landscape splits into three categories. Large hospice platforms (Amedisys-LHC Group / UnitedHealth, VITAS/Kindred, Compassus) acquire to expand geographic coverage and add palliative care capabilities to their hospice operations. Home health companies acquire palliative and hospice programs to offer a full post-acute continuum. And health system-affiliated PE funds acquire to build integrated serious illness management platforms.

The most competitive processes I've run in this space have involved all three buyer types bidding simultaneously. The strategic rationale is different for each — geographic fill-in for platforms, service line expansion for home health, capability building for PE — but they all converge on willing to pay premium multiples for quality organizations.

The Bottom Line

Palliative care and hospice organizations are benefiting from demographic tailwinds (aging population), regulatory evolution (expanding Medicare coverage for community-based palliative care), and growing awareness that serious illness management reduces total cost of care. Organizations that have built quality programs with strong metrics, diversified revenue streams, and clinical specialization (particularly pediatrics) are in high demand.

If you operate in this space, the most important thing you can do before going to market is ensure your quality data tells a compelling story. Star ratings, CAHPS scores, timely initiation rates, and compliance records aren't just regulatory obligations — they're the metrics that determine whether you get a premium or a discount. Invest in them accordingly.